Exploiting cell death pathways in regulatory T cells for cancer immunotherapy

Exploiting cell death pathways in regulatory T cells for cancer immunotherapy

Project details

Immunotherapies have revolutionised cancer therapy. Yet, despite clinical success, only a minority of patients treated show long-term clinical benefit and many malignancies remain to be targeted. Current immunotherapies block inhibitory pathways in tumour-resident T cells; however, interest in manipulating immune suppressive populations, such as FOXP3+ regulatory T (Treg) cells is growing.

This project will utilise unique pre-clinical models and patient cancer tissues to build on our discoveries targeting cell death processes in Treg cells and establish which cancers are best suited for a potential new immunotherapy. We will couple high-throughput single cell proteomics (CyTOF) and imaging approaches to uncover immune signatures that best predict responses.

About our research group

This project in the Gray laboratory is led by senior postdoctoral fellow Dr Charis Teh. It draws on funding from the National Health and Medical Research Council of Australia, and key cancer clinical collaborations in local Melbourne hospital (Royal Melbourne Hospital, Peter MacCallum Cancer Centre).

Researchers:

Associate Professor Daniel Gray

Associate Professor Daniel Gray
Associate Professor
Daniel
Gray
Joint Division Head
Charis Teh profile photo
Dr
Charis
Teh
Immunology division

Project Type: